<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "http://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial" dtd-version="1.1" specific-use="sps-1.9" xml:lang="pt">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id specific-use="scielo-v3" pub-id-type="publisher-id">65ktdT4cT4jmv9yJV4Bb5JR</article-id>
      <article-id specific-use="scielo-v2" pub-id-type="publisher-id">S0066-782X2026000101005</article-id>
      <article-id pub-id-type="doi">10.36660/abc.20250893</article-id>
      <article-id pub-id-type="other">01005</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Minieditorial</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Abla&#231;&#227;o por Campo Pulsado para Fibrila&#231;&#227;o Atrial: Experi&#234;ncia Inicial no Brasil</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-1349-1745</contrib-id>
          <name>
            <surname>Paix&#227;o</surname>
            <given-names>Gabriela Miana de Mattos</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="c1"/>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-3800-7107</contrib-id>
          <name>
            <surname>Bozzi</surname>
            <given-names>Isadora Cristine Reis Sguizzato</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <aff id="aff1">
          <label>1</label>
          <institution content-type="orgname">Universidade Federal de Minas Gerais</institution>
          <addr-line>
            <named-content content-type="city">Belo Horizonte</named-content>
            <named-content content-type="state">MG</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Universidade Federal de Minas Gerais, Belo Horizonte, MG &#8211; Brasil</institution>
        </aff>
      </contrib-group>
      <author-notes>
        <corresp id="c1"><label>Correspond&#234;ncia:</label><bold>Gabriela Miana de Mattos Paix&#227;o</bold> &#8226; Universidade Federal de Minas Gerais - Avenida Alfredo Balena, 110. CEP <postal-code>31270-901</postal-code>, Belo Horizonte, MG - Brasil E-mail: <email>gabimiana@gmail.com</email> </corresp>
      </author-notes>
      <pub-date date-type="pub" publication-format="electronic">
        <day>16</day>
        <month>03</month>
        <year>2026</year>
      </pub-date>
      <pub-date date-type="collection" publication-format="electronic">
        <year>2026</year>
      </pub-date>
      <volume>123</volume>
      <issue>1</issue>
      <elocation-id>e20250893</elocation-id>
      <history>
        <date date-type="received">
          <day>29</day>
          <month>12</month>
          <year>2025</year>
        </date>
        <date date-type="rev-recd">
          <day>06</day>
          <month>01</month>
          <year>2026</year>
        </date>
        <date date-type="accepted">
          <day>06</day>
          <month>01</month>
          <year>2026</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/" xml:lang="en">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License</license-p>
        </license>
      </permissions>
      <kwd-group xml:lang="pt">
        <title>Palavras-chave</title>
        <kwd>Arritmias Card&#237;acas</kwd>
        <kwd>Fibrila&#231;&#227;o Atrial</kwd>
        <kwd>Terapia de Eletropora&#231;&#227;o Irrevers&#237;vel</kwd>
      </kwd-group>
      <counts>
        <fig-count count="0"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="6"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <p>A fibrila&#231;&#227;o atrial (FA) &#233; a arritmia card&#237;aca sustentada mais comum na pr&#225;tica cl&#237;nica e representa um fardo significativo para a sa&#250;de p&#250;blica, pois est&#225; associada de forma independente &#224; redu&#231;&#227;o da qualidade de vida, ao aumento do risco de acidente vascular cerebral e &#224; mortalidade por todas as causas.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> A incid&#234;ncia e a preval&#234;ncia da FA est&#227;o aumentando em todo o mundo, impulsionadas principalmente pelo envelhecimento da popula&#231;&#227;o e pela crescente preval&#234;ncia de comorbidades cardiovasculares. Em conjunto, esses achados explicam o impacto econ&#244;mico da FA e seu papel como um desafio crescente para a sa&#250;de p&#250;blica.</p>
    <p>A abla&#231;&#227;o por cateter &#233; uma estrat&#233;gia bem estabelecida para o controle do ritmo na FA, tendo o isolamento das veias pulmonares como componente central, desde que os fatores desencadeantes relacionados &#224;s veias pulmonares foram identificados.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> Ao longo de mais de duas d&#233;cadas, os avan&#231;os no mapeamento eletroanat&#244;mico, na tecnologia de cateteres e na aplica&#231;&#227;o de energia melhoraram a seguran&#231;a e os resultados a longo prazo da abla&#231;&#227;o por radiofrequ&#234;ncia e crioabla&#231;&#227;o. Apesar desses avan&#231;os, o sucesso em um &#250;nico procedimento permanece limitado e podem ocorrer complica&#231;&#245;es relacionadas a les&#245;es t&#233;rmicas colaterais. A abla&#231;&#227;o por campo pulsado (PFA) surgiu recentemente como uma nova modalidade de abla&#231;&#227;o n&#227;o t&#233;rmica baseada na eletropora&#231;&#227;o, induzida por pulsos el&#233;tricos r&#225;pidos que ablacionam seletivamente o tecido mioc&#225;rdico, minimizando les&#245;es em estruturas adjacentes, como o es&#244;fago e o nervo fr&#234;nico. Estudos cl&#237;nicos iniciais e registros do mundo real demonstraram um perfil de seguran&#231;a favor&#225;vel e efic&#225;cia compar&#225;vel &#224; abla&#231;&#227;o t&#233;rmica.<sup><xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref></sup> No entanto, a otimiza&#231;&#227;o de protocolos e a obten&#231;&#227;o de dados robustos sobre os resultados a longo prazo continuam sendo necess&#225;rias, especialmente em pa&#237;ses de baixa e m&#233;dia renda, como o Brasil.</p>
    <p>O primeiro sistema PFA foi aprovado pela Ag&#234;ncia Nacional de Vigil&#226;ncia Sanit&#225;ria (ANVISA) apenas em abril de 2024. Portanto, seu uso no Brasil &#233; recente, e a literatura publicada dispon&#237;vel pode diferir dos resultados brasileiros devido a diferen&#231;as na infraestrutura de sa&#250;de, experi&#234;ncia do operador e demografia da popula&#231;&#227;o. Para preencher essa lacuna, &#193;vila et al.<sup><xref ref-type="bibr" rid="B5">5</xref></sup> realizaram o primeiro registro prospectivo brasileiro de 394 procedimentos PFA consecutivos realizados entre 18 de junho de 2024 e 29 de abril de 2025, em 60 centros participantes.</p>
    <p>A popula&#231;&#227;o estudada tinha uma idade m&#233;dia de 65 &#177; 12 anos, sendo 64% do sexo masculino. A FA parox&#237;stica foi a principal indica&#231;&#227;o em 62% dos pacientes, seguida pela FA persistente em 34%. O isolamento exclusivo das veias pulmonares foi o conjunto de les&#245;es predominante (54%), e o isolamento da parede posterior foi realizado em 168 pacientes (43%), seja durante o procedimento inicial ou em uma reinterven&#231;&#227;o. O n&#250;mero m&#233;dio de aplica&#231;&#245;es foi de 51 &#177; 16, com um tempo m&#233;dio total de procedimento de 113 &#177; 67 minutos. A anestesia geral foi realizada em 98% dos casos. A abla&#231;&#227;o guiada por fluoroscopia foi utilizada na maioria dos procedimentos, sendo que 75% dos procedimentos utilizaram mapeamento eletroanat&#244;mico 3D. Os procedimentos sem fluoroscopia (12%) apresentaram um n&#250;mero significativamente maior de aplica&#231;&#245;es (74&#177;22 vs. 48&#177;12, p&lt;0,001), tempos de abla&#231;&#227;o e de procedimento total mais longos (53&#177;14 vs. 40&#177;25 minutos, p=0,002 e 145&#177;37 vs. 106&#177;67 minutos, p&lt;0,001, respectivamente) em compara&#231;&#227;o com os procedimentos que utilizaram fluoroscopia. Nenhuma complica&#231;&#227;o grave foi relatada nesta s&#233;rie inicial.</p>
    <p>O estudo tamb&#233;m comparou os tr&#234;s centros com maior volume de procedimentos (Grupo I = 139 pacientes &#8211; 35%) com o restante do Grupo II (255 pacientes &#8211; 65%). Os centros com alto volume de procedimentos apresentaram tempos de procedimento e abla&#231;&#227;o significativamente menores (82 &#177; 27 vs. 131 &#177; 76 minutos; p &lt; 0,001 e 33 &#177; 14 vs. 50 &#177; 33 minutos; p &lt; 0,001, respectivamente), al&#233;m de menos les&#245;es adicionais ap&#243;s o remapeamento (7% vs. 30%; p &lt; 0,001), sugerindo uma curva de aprendizado r&#225;pida.</p>
    <p>Esses achados fornecem resultados encorajadores, consistentes com outras pesquisas internacionais,<sup><xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B6">6</xref></sup> e oferecem novas perspectivas relevantes sobre o uso atual da abla&#231;&#227;o por radiofrequ&#234;ncia para FA no Brasil. O procedimento demonstra alta seguran&#231;a aguda e uma curva de aprendizado curta, como evidenciado pela efici&#234;ncia de operadores com grande volume de procedimentos. Entretanto, esta &#233; uma revis&#227;o importante, por&#233;m preliminar. Os autores reconhecem que a falta de acompanhamento &#233; uma limita&#231;&#227;o que deve ser abordada em pesquisas futuras por meio de estudos de desfecho em longo prazo. Al&#233;m disso, an&#225;lises de custo-efetividade tamb&#233;m s&#227;o necess&#225;rias para avaliar a viabilidade da incorpora&#231;&#227;o dessa tecnologia aos planos de sa&#250;de e ao sistema p&#250;blico de sa&#250;de brasileiros.</p>
  </body>
  <back>
    <fn-group>
      <fn fn-type="other" id="fn1">
        <label>Minieditorial referente ao artigo:</label>
        <p>Abla&#231;&#227;o por Campo Pulsado para Fibrila&#231;&#227;o Atrial: Experi&#234;ncia Multic&#234;ntrica Inicial no Brasil</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>Refer&#234;ncias</title>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cintra</surname>
              <given-names>FD</given-names>
            </name>
            <name>
              <surname>Pisani</surname>
              <given-names>CF</given-names>
            </name>
            <name>
              <surname>Rezende</surname>
              <given-names>AGDS</given-names>
            </name>
            <name>
              <surname>Henz</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Armaganijan</surname>
              <given-names>LV</given-names>
            </name>
            <name>
              <surname>Pimentel</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Brazilian Atrial Fibrillation Guidelines - 2025</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2025</year>
          <volume>122</volume>
          <issue>9</issue>
          <elocation-id>e20250618</elocation-id>
          <pub-id pub-id-type="doi">10.36660/abc.20250618</pub-id>
        </element-citation>
        <mixed-citation>1 Cintra FD, Pisani CF, Rezende AGDS, Henz BD, Armaganijan LV, Pimentel M, et al. Brazilian Atrial Fibrillation Guidelines - 2025. Arq Bras Cardiol. 2025;122(9):e20250618. doi: 10.36660/abc.20250618.</mixed-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Turagam</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Neuzil</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Reichlin</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Neven</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Metzner</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Safety and Effectiveness of Pulsed Field Ablation to Treat Atrial Fibrillation: One-Year Outcomes From the MANIFEST-PF Registry</article-title>
          <source>Circulation</source>
          <year>2023</year>
          <volume>148</volume>
          <issue>1</issue>
          <fpage>35</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.123.064959</pub-id>
        </element-citation>
        <mixed-citation>2 Turagam MK, Neuzil P, Schmidt B, Reichlin T, Neven K, Metzner A, et al. Safety and Effectiveness of Pulsed Field Ablation to Treat Atrial Fibrillation: One-Year Outcomes From the MANIFEST-PF Registry. Circulation. 2023;148(1):35-46. doi: 10.1161/CIRCULATIONAHA.123.064959.</mixed-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reddy</surname>
              <given-names>VY</given-names>
            </name>
            <name>
              <surname>Gerstenfeld</surname>
              <given-names>EP</given-names>
            </name>
            <name>
              <surname>Natale</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Whang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Cuoco</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation</article-title>
          <source>N Engl J Med</source>
          <year>2023</year>
          <volume>389</volume>
          <issue>18</issue>
          <fpage>1660</fpage>
          <lpage>1671</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa2307291</pub-id>
        </element-citation>
        <mixed-citation>3 Reddy VY, Gerstenfeld EP, Natale A, Whang W, Cuoco FA, Patel C, et al. Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2023;389(18):1660-71. doi: 10.1056/NEJMoa2307291.</mixed-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iqbal</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Amador</surname>
              <given-names>WFO</given-names>
            </name>
            <name>
              <surname>Cevallos-Cueva</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ahmad</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Alarc&#243;n</surname>
              <given-names>JAP</given-names>
            </name>
            <name>
              <surname>Diniz</surname>
              <given-names>RV</given-names>
            </name>
          </person-group>
          <article-title>Pulsed Field Ablation versus Very High-Power Short-Duration Radiofrequency Ablation in Atrial Fibrillation: A Systematic Review and Meta-Analysis</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2025</year>
          <volume>122</volume>
          <issue>7</issue>
          <elocation-id>e20240845</elocation-id>
          <pub-id pub-id-type="doi">10.36660/abc.20240845</pub-id>
        </element-citation>
        <mixed-citation>4 Iqbal A, Amador WFO, Cevallos-Cueva M, Ahmad M, Alarc&#243;n JAP, Diniz RV. Pulsed Field Ablation versus Very High-Power Short-Duration Radiofrequency Ablation in Atrial Fibrillation: A Systematic Review and Meta-Analysis. Arq Bras Cardiol. 2025;122(7):e20240845. doi: 10.36660/abc.20240845.</mixed-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>May</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Araujo</surname>
              <given-names>N</given-names>
              <suffix>Junior</suffix>
            </name>
            <name>
              <surname>Boghossian</surname>
              <given-names>SHC</given-names>
            </name>
            <name>
              <surname>Atie</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Maciel</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Hardy</surname>
              <given-names>CA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Brazilian Registry of Pulsed Field Catheter Ablation for the Treatment of Patients with Atrial Fibrillation</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2026</year>
          <volume>123</volume>
          <issue>1</issue>
          <elocation-id>e20250416</elocation-id>
          <comment>
            <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.36660/abc.20250416">https://doi.org/10.36660/abc.20250416</ext-link>
          </comment>
        </element-citation>
        <mixed-citation>5 May BM, Araujo Junior N, Boghossian SHC, Atie J, Maciel WA, Hardy CA, et al. Brazilian Registry of Pulsed Field Catheter Ablation for the Treatment of Patients with Atrial Fibrillation. Arq Bras Cardiol. 2026; 123(1):e20250416. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.36660/abc.20250416">https://doi.org/10.36660/abc.20250416</ext-link>.</mixed-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Verma</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Haines</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Boersma</surname>
              <given-names>LV</given-names>
            </name>
            <name>
              <surname>Sood</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Natale</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Marchlinski</surname>
              <given-names>FE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial</article-title>
          <source>Circulation</source>
          <year>2023</year>
          <volume>147</volume>
          <issue>19</issue>
          <fpage>1422</fpage>
          <lpage>1432</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.123.063988</pub-id>
        </element-citation>
        <mixed-citation>6 Verma A, Haines DE, Boersma LV, Sood N, Natale A, Marchlinski FE, et al. Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial. Circulation. 2023;147(19):1422-32. doi: 10.1161/CIRCULATIONAHA.123.063988.</mixed-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="S1" xml:lang="en">
    <front-stub>
      <article-id pub-id-type="doi">10.36660/abc.20250893i</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Short Editorial</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Pulsed Field Ablation for Atrial Fibrillation: Early Experience in Brazil</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-1349-1745</contrib-id>
          <name>
            <surname>Paix&#227;o</surname>
            <given-names>Gabriela Miana de Mattos</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="c2"/>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-3800-7107</contrib-id>
          <name>
            <surname>Bozzi</surname>
            <given-names>Isadora Cristine Reis Sguizzato</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>1</sup>
          </xref>
        </contrib>
        <aff id="aff2">
          <label>1</label>
          <addr-line>
            <named-content content-type="city">Belo Horizonte</named-content>
            <named-content content-type="state">MG</named-content>
          </addr-line>
          <country country="BR">Brazil</country>
          <institution content-type="original">Universidade Federal de Minas Gerais, Belo Horizonte, MG &#8211; Brazil</institution>
        </aff>
      </contrib-group>
      <author-notes>
        <corresp id="c2"><label>Mailing Address:</label><bold>Gabriela Miana de Mattos Paix&#227;o</bold> &#8226; Universidade Federal de Minas Gerais - Avenida Alfredo Balena, 110. Postal Code <postal-code>31270-901</postal-code>, Belo Horizonte, MG - Brazil E-mail:<email>gabimiana@gmail.com</email> </corresp>
      </author-notes>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Cardiac Arrhythmias</kwd>
        <kwd>Atrial Fibrillation</kwd>
        <kwd>Irreversible Electroporation Therapy</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in clinical practice and represents a significant public health burden because it is independently associated with impaired quality of life, increased risk of stroke, and all-cause mortality<sup>(1)</sup>. The incidence and prevalence of AF are growing worldwide, driven mainly by population aging and the rising prevalence of cardiovascular comorbidities. Together, these findings explain the economic impact of AF and its role as a growing healthcare challenge.</p>
      <p>Catheter ablation is a well-established rhythm-control strategy for AF, with pulmonary vein isolation as its central component, since pulmonary vein&#8211;related triggers were recognized.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> Over more than two decades, advances in electroanatomic mapping, catheter technology, and energy delivery have improved the safety and long-term outcomes of radiofrequency and cryoballoon ablation. Despite these advances, single-procedure success remains limited, and complications related to collateral thermal injury can occur. Pulsed field ablation (PFA) has recently emerged as a novel, nonthermal ablation modality based on electroporation, induced by rapid electrical pulses that selectively ablate myocardial tissue while minimizing injury to adjacent structures such as the esophagus and phrenic nerve. Early clinical studies and real-world registries have demonstrated a favorable safety profile and efficacy comparable to thermal ablation.<sup><xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref></sup> However, optimizing protocols and obtaining robust long-term outcome data remain necessary, especially in low- and middle-income countries such as Brazil.</p>
      <p>The first PFA system was approved by the Brazilian Health Regulatory Agency (ANVISA) only in April 2024. Hence, its use in Brazil is recent, and the available published literature may differ from Brazilian results due to differences in healthcare infrastructure, operator experience, and population demographics. To fill this gap, Avila et al.<sup><xref ref-type="bibr" rid="B5">5</xref></sup> conducted the first Brazilian prospective registry of 394 consecutive PFA procedures performed between June 18, 2024, and April 29, 2025, at 60 participating centers.</p>
      <p>The study population had a mean age of 65 &#177; 12 years, and 64% were male. Paroxysmal AF was the primary indication in 62% of patients, followed by persistent AF in 34%. Pulmonary vein isolation-only was the dominant lesion set (54%), and posterior wall isolation was performed in 168 patients (43%) either during the index or a redo procedure. The mean number of applications was 51 &#177; 16, with a total mean procedure time of 113 &#177; 67 minutes. General anesthesia was performed in 98% of the cases. Fluoroscopy-guided ablation was used in most procedures, with 75% of procedures using 3D electroanatomical mapping. Fluoroless procedures (12%) had a significantly higher number of applications (74&#177;22 vs. 48&#177;12, p&lt;0.001), longer ablation and total procedure times (53&#177;14 vs. 40&#177;25 minutes, p=0.002 and 145&#177;37 vs. 106&#177;67 minutes, p&lt;0.001, respectively) as compared to procedures using fluoroscopy. No major complications were reported during this initial series.</p>
      <p>The study also compared the three highest-volume operators (Group I = 139 patients &#8211; 35%) with the remaining Group II (255 patients &#8211; 65%). High-volume centers had significantly shorter procedure and ablation times (82 &#177; 27 vs. 131 &#177; 76 minutes; p &lt;0.001 and 33 &#177; 14 vs. 50 &#177; 33 minutes; p &lt;0.001, respectively), alongside fewer additional lesions after remapping (7% vs. 30%; p&lt;0.001), suggesting a rapid learning curve.</p>
      <p>These findings provide encouraging results consistent with other international research<sup><xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B6">6</xref></sup> and offer new, relevant insights into the current use of PFA for AF in Brazil. It demonstrates high acute safety and a short learning curve, as evidenced by the efficiency of high-volume operators. However, this is an important, but preliminary overview. The authors acknowledge that the lack of follow-up is a limitation, which should be addressed in future research through long-term outcome studies. Furthermore, cost-effectiveness analyses are also warranted to evaluate the feasibility of incorporating this technology into Brazilian health insurance plans and the public health system.</p>
    </body>
    <back>
      <fn-group>
        <fn fn-type="other" id="fn2">
          <label>Short Editorial related to the article:</label>
          <p>Brazilian Registry of Pulsed Field Catheter Ablation for the Treatment of Patients with Atrial Fibrillation</p>
        </fn>
      </fn-group>
    </back>
  </sub-article>
</article>
